The Omeros Building
201 Elliott Avenue West
Seattle, WA 98119
United States
206 676 5000
https://www.omeros.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 198
Nombre | Título | Paga | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Dr. Gregory A. Demopulos M.D. | Co-Founder, Chairman, CEO & President | 1,79M | N/A | 1959 |
Mr. Michael A. Jacobsen | Chief Accounting Officer, VP of Finance & Treasurer | 518,6k | N/A | 1958 |
Mr. Peter B. Cancelmo J.D. | VP, General Counsel & Corporate Secretary | 503,24k | N/A | 1979 |
Dr. Pamela Pierce Palmer M.D., Ph.D. | Co-Founder | N/A | N/A | 1963 |
Dr. George A. Gaitanaris M.D., Ph.D. | Chief Scientific Officer & VP of Science | N/A | N/A | 1957 |
Mr. Peter W. Williams | Vice President of Human Resources | N/A | N/A | 1968 |
Dr. Catherine A. Melfi Ph.D. | Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems | N/A | N/A | 1959 |
Ms. Nadia Dac | VP & Chief Commercial Officer | N/A | N/A | 1970 |
Dr. Andreas Grauer M.D. | VP & Chief Medical Officer | N/A | N/A | 1961 |
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
El ISS Governance QualityScore de Omeros Corporation, a día 1 de mayo de 2024, es 7. Las puntuaciones base son Auditoría: 8; Tablero: 9; Derechos de los accionistas: 5; Compensación: 8.